Please login to the form below

Not currently logged in

Boehringer stays ahead of the curve

Boehringer Ingelheim revealed that its performance to the end of 2007 has 'outpaced' the market for the eighth consecutive year
Boehringer Ingelheim revealed that its performance to the end of 2007 has 'outpace' the market for the eighth consecutive year.

Boehringer recorded turnover went up from $10.5bn in 2006 to almost $11bn in 2007, a rise of 8.8 per cent in local currency (3.3 per cent in euro terms).

"The fact that Boehringer successfully achieved growth of 3.6 per cent in euro terms despite these challenges highlights the excellent dynamic growth of its product portfolio," the company said in a statement.

According to Boehringer, the company overcame several challenges in 2007 including US patent expiry for its product Mobic. Net sales of the arthritis painkiller fell by $340m and needed to be offset.

Dr Alessandro Banchi, chairman of the board of managing directors for Boehringer and head of corporate board division of pharma marketing and sales, said: "We can look back once again on a successful year for Boehringer Ingelheim with continued growth in 2007. Our products are benefiting patients, our product pipeline is well equipped and our workforce is highly motivated."

The company's healthy financial position allowed for the creation of 1,400 new jobs, bringing Boehringer's employee total to 39,800, a rise of 3.6 per cent. Boehringer has, since 2003, recruited an additional 5,500 members of staff, an overall increase of 16 per cent for the four-year period.

The company came first in the 2007 Top Employers Survey conducted by the journal Science that named it as the most attractive employer in the science community in Europe and the US.

8th April 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....